BioSpace News Archive

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application for Dupixent® to treat children aged 1 to 11 years with eosinophilic esophagitis.

POXEL SA, a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis and rare metabolic disorders, announced its financial results for the period ended June 30, 2023 and provided a corporate update.

Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat, and prevent within the field of hearing loss disorders, Sensorion announces the availability of its 1st Half 2023 Financial Report to the public and filed with the Autorité des marchés financiers.

OMass Therapeutics announces the appointment of Mark Namchuk, PhD to its Scientific Advisory Board.

Profuse Technology is excited to announce a breakthrough in its cutting-edge technology that is poised to reshape the landscape of muscle production in 3D format on scaffolds.

Beactica Therapeutics AB, the Swedish precision oncology company, announced that it has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences, one of 27 institutes and centers at the U.S. National Institutes of Health.

WuXi Vaccines, a leading contract development and manufacturing organization focused on vaccine discovery, development, and manufacturing, has launched its first standalone vaccines CDMO site in Suzhou, China.

Oxford BioDynamics, Plc. announced validation of its EpiSwitch Prostate Screening blood test in its US clinical laboratory, resulting in the immediate access to its highly accurate PSE test to men with prostate cancer risk.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is the first CTDMO to offer integrated services for all critical stages of mRNA development, manufacturing, and commercialization, including products and testing.

AlzeCure Pharma announced that an abstract with preclinical data on NeuroRestore ACD856 demonstrating its potential disease-modifying effects has been accepted for presentation at the annual Alzheimer’s conference CTAD, Clinical Trials in Alzheimer’s Disease, which this year is being held in Boston on October 24-27.